Interaction of paraoxonase-192 polymorphism with low HDL-cholesterol in coronary artery disease risk;Interacçao entre o polimorfismo 192 da paraoxonase e os baixos níveis de colesterol-HDL no risco de doença coronária [41]

Revista Portuguesa de Cardiologia

Volumn 29, Issue 4, 2010, Pages 571-580

  Mendonça, Maria Isabel ^a   Dos Reis, Roberto Palma ^a   Freitas, Ana Isabel ^a   Pereira, Andrem ^a   Sousa, Ana Célia ^a   Freitas, Sónia ^a   Ornelas, Ilídio ^a   Freitas, Carolina ^a   Brehm, António ^a   Araújo, José Jorge ^a  

^a NONE

Author keywords

Coronary disease; HDL cholesterol; Paraoxonase 1; Polymorphisms; Risk factors

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B100; ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ARYLDIALKYLPHOSPHATASE; PON1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; RISK FACTOR;

ARYLDIALKYLPHOSPHATASE; CHOLESTEROL, HDL; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 77957343238     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991; 286:152-154.
2. Bhattacharyya T, Nicholls S J, Topol E J, Zhang R, Yang Xia, Schmitt, BA; Xiaoming David F, Shao M, Brennan Danielle M, Ellis SG, Brennan ML, Allayee H, Lusis AJ, Hazen S L. Relationship of Paraoxonase 1 (PON1) Gene Polymorphisms and Functional Activity with Systemic Oxidative Stress and Cardiovascular Risk. JAMA. 2008; 299(11):1265-1276.
3. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol. 1996; 7:69-76.
4. Durrington PN, Mackness B, Mackness MI. Paraoxonase and Atherosclerosis. 2001, Arterioscler Thromb Vasc Biol, 2001;21:473-480.
5. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest. 1995; 96:3005-3008.
6. Pfohl M, Koch M, Enderle MD, Kühn R, Füllhase J, Karsch KR, Haring HU. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes. 1999 48:623-627; doi:10.2337/diabetes.48.3.623
7. Jauhiainen M, Frick MH, Ehnholm C. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary heart disease in Finns. J Clin Invest. 1996; 98:883-885.
8. Chobanian AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). JAMA, 2003; 289:2560-2572.
9. Report of the Expert Committee on Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997, 1183-1197.
10. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D. European Society of Cardiology. American Heart Association. American College of Cardiology. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis. (2004); 173:381-391.
11. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEPT) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
12. Rothman KJ (1974) Synergy and antagonism in cause-effect relationships. Am J Epidemiol 99:385-388.
13. Khoury MJ, Flanders WD. Non-traditional epidemiologic approaches in the analysis of gene-environment interaction: case-control studies with no controls! Am J Epidemiol.1996; 144:207-213.
14. Mackness B, Durrington PN, Abuashia B, Boulton AJ, Mackness MI. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci (Lond). 2000;98(3):355-63.
15. Senti M, Tomás M, Marrugate J, Elosura R, for the REGICOR Investigators. Paraoxonase 1 192 Polymorphism Modulates the Nonfatal Myocardial Infarction Risk Associated with Decreased HDLs. Arterioscler Thromb Vasc Biol. 2001;21:415-420.